Analyst Price Target is $37.25
▲ +55.86% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for MBX Biosciences in the last 3 months. The average price target is $37.25, with a high forecast of $44.00 and a low forecast of $30.00. The average price target represents a 55.86% upside from the last price of $23.90.
Current Consensus is
Buy
The current consensus among 4 investment analysts is to buy stock in MBX Biosciences.
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
Read More
